Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2024 09:45 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor

Palm Beach Gardens, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel...
March 31, 2024 19:00 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company...
March 22, 2024 09:45 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

Palm Beach Gardens, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel...
April 06, 2023 08:01 ET | Source: Ocean Biomedical, Inc.

Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome

On Hermansky-Pudlak Syndrome (HPS) Awareness Day, Ocean Biomedical announces a commitment to developing viable treatment options for HPS-1 and HPS-4 Providence, RI, April 06, 2023 ...
November 24, 2021 15:05 ET | Source: Curative Biotechnology, Inc. 

[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
November 24, 2021 10:00 ET | Source: Curative Biotechnology, Inc. 

CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
April 29, 2021 10:12 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”

Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board Boca Raton, FL, April 29, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) a...
March 09, 2021 10:24 ET | Source: Connectyx Technologies Holdings Group, Inc

Connectyx Reports Fiscal Year 2020 Financial Results

Biotechnology Company Issues Highlights and Subsequent Events Boca Raton, Fla, March 09, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the...
October 16, 2020 11:00 ET | Source: Connectyx Technologies Holdings Group, Inc

Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma

Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...